BLK
54
4
ACN
54
4
BRK.B
25
3
FITB
35
2
PEG
57
2
TEL
60
2
FOX
73
3
LOW
46
3
PRU
47
2
MMC
50
4
GLW
48
4
PEP
36
3
EXPE
88
2
MSFT
58
4
V
76
8
VRSK
59
5
EMR
62
6
ZTS
40
2
HP
38
4
WAT
59
4
BLK
54
4
ACN
54
4
BRK.B
25
3
FITB
35
2
PEG
57
2
TEL
60
2
FOX
73
3
LOW
46
3
PRU
47
2
MMC
50
4
GLW
48
4
PEP
36
3
EXPE
88
2
MSFT
58
4
V
76
8
VRSK
59
5
EMR
62
6
ZTS
40
2
HP
38
4
WAT
59
4
Financhill
Back

Materialise NV 10K Form

Sell
39

MTLS
Materialise NV

Last Price:
$7.37
Seasonality Move:
-15.67%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MTLS News And Ratings

See the #1 stock for the next 7 days that we like better than MTLS

MTLS Financial Statistics

Sales & Book Value

Annual Sales: $277.3M
Cash Flow: $-341.5K
Price / Cash Flow: 90.71
Annual Sales: $4.67
Price / Book: 1.57

Profitability

EPS (TTM): 0.18480
Net Income (TTM): $11.2M
Gross Margin: $157.1M
Return on Equity: 4.27%
Return on Assets: 2.6%

Materialise NV Earnings Forecast

Key Materialise NV Financial Ratios

  • The Gross Profit Margin over the past 12 years for MTLS is 56.66%.
  • The Selling, General & Administrative Expenses for MTLS have been equal to 35.23% of Gross Profit Margin.
  • The Research & Development expenses have been 14.87% of Revenue.
  • The Interest Expense is 26.05% of Operating Income.
  • The Net Earning history of MTLS is 2.62% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Materialise NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Software
Sector: Information Technology
Current Symbol: MTLS
CUSIP: 57667T
Website: materialise.com

Debt

Debt-to-Equity Ratio: 0.18
Current Ratio: 1.81
Quick Ratio: 1.54

Price-to-Earnings

Trailing P/E Ratio: 61.55
Forward P/E Ratio: 25.4

MTLS Technical Analysis vs Fundamental Analysis

Sell
39
Materialise NV (MTLS) is a Sell

Is Materialise NV a Buy or a Sell?

  • Materialise NV stock is rated a Sell
    The current Materialise NV [MTLS] share price is $7.33. The Score for MTLS is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.